CervoMed Reports Positive Results from Alzheimer's Clinical Trial
Cervomed announced that, in a late-breaking oral session at the 18th Clinical Trials on Alzheimer's Disease Conference in San Diego, California, clinical investigators shared the full results of the Phase 2b RewinD-LB trial of neflamapimod, being developed by CervoMed for the treatment of dementia with Lewy bodies, or DLB. In the trial, neflamapimod demonstrated a significant and clinically meaningful effect on multiple outcomes in DLB patients, including on the primary outcome measure, change in CDR sum-of-boxes. These positive clinical outcomes were correlated with observed reductions in glial fibrillary acidic protein, a biomarker of neuronal damage, supporting neflamapimod's mode of action targeting the underlying mechanism of DLB. A significant improvement on the primary endpoint, CDR-SB, at week 16 of the extension phase, with a mean change that was 52% lower with DP Batch B compared to DP Batch A in all participants and 82% lower in patients. The clinical effect in CDR-SB was durable to 32 weeks, with a 65% reduction in clinical worsening in all participants and an 89% reduction in clinical worsening in the less than21.0 pg/mL ptau181 subgroup. In addition, neflamapimod was well-tolerated with a low rate of treatment discontinuation over 48 weeks of treatment during the trial.
Trade with 70% Backtested Accuracy
Analyst Views on CRVO
About CRVO
About the author
Biotech Insider Buying Signals Strong, Three Companies Draw Attention
- Insider Buying Signals: Summit Therapeutics has recently seen insider purchases, indicating management's confidence in its cancer drug's market potential, which could lead to significant stock price volatility in the future.
- Neurological Drug Development: Annexon also reported insider buying, reflecting confidence in its antibody drugs targeting neurological diseases, despite the high clinical trial risks, the potential for success is substantial.
- Cognitive Disorder Treatment: CervoMed's insider trading is noteworthy as its drug for Lewy body dementia shows market expectations for new therapies, although challenges in clinical trials remain significant.
- Investor Strategy: Insider buying in biotech stocks is not a buy signal but a research prompt, urging investors to carefully assess company cash flow and market sentiment to avoid losses from market fluctuations.
CervoMed's Neflamapimod Shows Significant Improvement in DLB Patients in Phase 2b Trial
- Clinical Trial Results: CervoMed's Phase 2b RewinD-LB trial demonstrated that neflamapimod significantly improved CDR-SB scores in DLB patients, achieving a 52% reduction compared to placebo over 16 weeks, indicating its potential as a treatment.
- Biomarker Improvement: The treatment group showed a significant reduction in GFAP levels, suggesting that neflamapimod effectively targets neurodegenerative processes, reinforcing its scientific basis as a potential DLB therapy.
- Future Trial Plans: CervoMed is set to initiate a global Phase 3 registrational trial in the second half of 2026 to further validate neflamapimod's efficacy, advancing its path to market.
- Funding Support: The RewinD-LB trial received $21.3 million in NIH funding, covering 43 research sites across the U.S., U.K., and Netherlands, highlighting the broad support and potential impact of this research.
